News2020-06-29T17:45:33+01:00

News

Glucose Binding Molecules that could revolutionize diabetes management.

Glucose Binding Molecules that could revolutionize diabetes management. Carbometrics is one of the latest companies to feature in the web series ‘Science in Action' by Horiba scientific, which showcases cutting edge and innovative companies using their state-of-the-art analysis equipment. Head of Research Dr Rob Tromas and Research Operations Manager Stacy Coomber discuss the story behind the company, the science and the huge potential of the team's glucose receptor. “Scientists [...]

May 17th, 2021|

Carbometrics secure their latest funding round totalling £2.1m from investors.

Science Creates Ventures Announces Second Investment From Its EIS Fund 1. Science Creates Ventures has made the second investment from its EIS fund 1 into Carbometrics, leading a £2.1m round with a syndicate of investors. Carbometrics, the spin-out of Ziylo, is developing a supramolecular Glucose Binding Molecule platform, working towards reliable, accurate and long-lasting glucose sensors. Andy Chapman, CEO of Carbometrics says: “This investment provides the runway that the company needs to [...]

May 5th, 2021|

Sensing with biomimetic glucose binding molecules.

Photo credit: TTP   Sensing with biomimetic glucose binding molecules. Carbometrics and TTP have combined their proficiencies to develop a range of glucose sensing solutions;  Carbometrics in the design and synthesis of highly selective and robust binding molecules and TTP’s expertise in electrochemistry, sensor transduction technologies. Carbometrics worked with TTP to understand how their unique ability to design, synthesise and derive highly selective and robust small molecule [...]

September 22nd, 2020|

Carbometrics CEO Receives Royal Society of Chemistry’s Prestigious Rising Star in Industry Award.

    Carbometrics CEO Receives Royal Society of Chemistry’s Prestigious Rising Star in Industry Award.   Dr Andrew Chapman is the CEO and Co-founder at Carbometrics, a company that was spun out from Ziylo Ltd, where he was previously CSO prior to it’s sale to Novo Nordisk in 2018. The Royal Society of Chemistry recognised Andy for “leading the scientific team of a small diabetes spin-out company towards one [...]

June 26th, 2020|
Go to Top